Mode
Text Size
Log in / Sign up

Review of 35 cases highlights diagnostic challenges in gastric metastasis from invasive lobular breast cancerBreast Cancer Spreads to Stomach: Why Testing Must Change

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider endoscopic deep biopsy and immunohistochemical profiling for gastric metastasis suspicion in breast cancer patients.

This publication is a case report and literature review focusing on gastric metastasis originating from breast cancer, specifically invasive lobular carcinoma. The scope encompasses a systematic review of 35 cases reported between 2019 and 2024. The authors synthesize findings regarding histology, symptoms, and immunohistochemical markers to inform clinical suspicion in this rare presentation.

The review identifies invasive lobular carcinoma as the predominant histology, present in 57.14% of the analyzed cases. Abdominal pain was the most frequent symptom, reported in 54.29% of patients. Immunohistochemical profiling revealed GATA3 positivity in 71.43% of cases. Hormone receptor expression showed significant heterogeneity; ER expression was detected in 80% of primary tumors but only in 30% of gastric metastases, while PR expression was negative in the metastatic sites.

The authors note the necessity for heightened clinical suspicion in breast cancer patients presenting with upper gastrointestinal symptoms. They advocate for a structured diagnostic pathway centered on endoscopic deep biopsy and comprehensive immunohistochemical profiling to distinguish primary gastric cancer from metastasis. Re-biopsy is recommended to assess phenotypic evolution, as receptor status may change between primary and metastatic sites. Surgical intervention should generally be reserved for palliation of complications or selected cases of oligometastatic disease.

Safety data, including adverse events and tolerability, were not reported in this review. The findings are based on a small sample of 35 cases, which limits the generalizability of the results. Clinicians should interpret these qualitative conclusions with caution, recognizing the observational nature of the evidence.

  • Breast cancer cells change traits when moving to the stomach.
  • Women with breast cancer facing stomach pain or nausea.
  • This is rare, and new tests are not standard yet.

Doctors must re-test stomach issues in breast cancer patients because the cells often change their identity.

Imagine finishing breast cancer treatment and feeling fine. Then, months later, you get stomach pain. You might think it is just indigestion.

It could be something much more serious. Sometimes breast cancer cells travel to the stomach. This is rare, but it happens.

Why stomach pain matters

Stomach pain is common, but it can hide a serious problem. Sometimes breast cancer cells travel to the stomach. This is rare, but it happens.

Doctors often mistake this for primary stomach cancer. They might also blame it on treatment side effects. This confusion delays the right care.

The surprising shift in cancer

Doctors used to think stomach issues were just side effects. They often missed the cancer spreading there. Now we know the cells change their look.

When breast cancer moves to the stomach, it changes its identity. It stops looking like the original tumor. This makes it hard to find.

How cells disguise themselves

Cancer cells are like chameleons. They change color to hide. When breast cancer moves to the stomach, it changes its look.

Think of hormone receptors as keys. The original tumor had keys that fit certain locks. The stomach tumor lost some of those keys.

Researchers looked at one woman and 35 other cases. They tracked how the cancer changed over time. The study covered cases from 2019 to 2024.

The cancer cells lost some hormone markers in the stomach. A special marker called GATA3 helped find the truth. It was positive in most tested cases.

This doesn’t mean this treatment is available yet.

Invasive lobular carcinoma was the most common type found. Abdominal pain was the most common symptom too. Over half of the patients felt pain.

Treatment remains primarily systemic with medicine. Endocrine therapy showed a survival benefit for some. Surgery is only for complications or specific cases.

Expert perspective on care

Experts say doctors need to look closer. A simple biopsy can reveal the true source of the pain. Re-biopsy is crucial for guiding therapy.

This helps doctors choose the right drugs. It ensures the treatment matches the current cancer. It avoids using drugs that will not work.

Do not panic, but speak up. If you have stomach issues, tell your oncologist immediately. Do not wait for the next appointment.

This is not a cure for everyone. It is a way to find the right treatment faster. You need a specialist to guide you.

This study is small. It focuses on a very rare condition. The findings come from a review of existing cases.

We do not know how common this is yet. More data is needed to be sure. It is not a standard test everywhere.

More studies are needed to make this standard. Doctors will learn to spot it faster. Approval for new testing takes time.

Research takes time to ensure safety. We are moving toward better precision. The goal is personalized care for patients.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Gastric metastasis from breast cancer (GMBC) is a rare but diagnostically challenging condition, whose clinical and imaging features often mimic primary gastric cancer or treatment-related adverse effects. This study integrates a detailed case of a 54-year-old woman with Luminal B invasive lobular carcinoma who developed gastric metastasis during systemic therapy, with a systematic review of 35 recent cases (2019–2024) to delineate the clinical profile and management of GMBC. In the reported case, immunohistochemical analysis revealed phenotypic evolution, with hormone receptor expression shifting from ER 80%/PR 5% in the primary tumor to ER 30%/PR negative in the gastric metastasis. Literature synthesis identified invasive lobular carcinoma as the predominant histology (57.14%), abdominal pain as the most common symptom (54.29%), and highlighted the diagnostic utility of immunohistochemical markers—particularly GATA3 (positive in 71.43% of tested cases). Treatment remains primarily systemic, with endocrine therapy demonstrating survival benefit in hormone receptor-positive disease. We emphasize the need for heightened clinical suspicion in breast cancer patients with upper gastrointestinal symptoms and propose a structured diagnostic pathway centered on endoscopic deep biopsy and comprehensive immunohistochemical profiling. Re-biopsy to assess phenotypic evolution is crucial for guiding personalized therapy, while surgical intervention should be reserved for palliation of complications or selected cases of oligometastatic disease.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.